Voloridge Investment Management
BTAI icon

Voloridge Investment Management’s BioXcel Therapeutics BTAI Stock Holding History

Voloridge Investment Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,160
Closed -$645K – 1369
2023
Q1 		$645K Buy
+2,160
New +$922K ﹤0.01% 1191
2022
Q4 		– Sell
-5,562
Closed -$1.05M – 1446
2022
Q3 		$1.05M Sell
5,562
-826
-13% -$192K 0.01% 1148
2022
Q2 		$1.35M Buy
+6,388
New +$1.34M 0.01% 1121

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Voloridge Investment Management's BTAI Position: Q2 2023 in Review

Voloridge Investment Management sold out of BioXcel Therapeutics (BTAI) in Q2 2023, closing a stake of 2,160 shares — an estimated $645K sold.

Voloridge Investment Management first reported a position in BTAI in Q2 2022 and held it in 3 quarters. The position peaked at $1.35M in Q2 2022. 88 funds tracked by Wall St. Rank hold BTAI as of Q2 2023.

  • Voloridge Investment Management reported no remaining BioXcel Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Voloridge Investment Management sold 2,160 BioXcel Therapeutics shares in Q2 2023, an estimated $645K.
  • Voloridge Investment Management first reported a position in BioXcel Therapeutics in Q2 2022 and held it in 3 quarters.
  • Voloridge Investment Management's BioXcel Therapeutics position peaked at $1.35M in Q2 2022.
  • 88 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2023.

Based on Voloridge Investment Management's 13F filing for Q2 2023, filed 14 Aug 2023.